Drug
Lobaplatin clinical trials
- studies test it
- 16
- open now
- 6
- in phase 3
- 4
- first study started
- 2009
Keep track of what changes. Save the lobaplatin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 10
- Phase 3
- 4
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 16
Wuhan Union Hospital, China (2) · Zhujiang Hospital (2) · Henan Cancer Hospital (1) · Fifth Affiliated Hospital, Sun Yat-Sen University (1) · Shandong Cancer Hospital and Institute (1) · Xijing Hospital (1) · Chinese Academy of Medical Sciences (1) · Guizhou Medical University (1)
Often tested with
Tested in the same studies.
Fluorouracil (4) · Leucovorin (3) · Paclitaxel (2) · Oxaliplatin (2) · Cisplatin (2) · Raltitrexed (2) · Adebrelimab (1) · Mitomycin (1)
Studies
Open first, then newest update. How each study uses lobaplatin is read from its arms, and is right about nine times in ten.
Testing it · 16
- Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast CancerNot yet recruitingPhase 4Shandong Cancer Hospital and InstituteNCT07093931Written as lobaplatin
- Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction CarcinomaNot yet recruitingPhase 2Xijing HospitalNCT06198465Written as adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil
- Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled TrialRecruitingPhase 3Zhujiang HospitalNCT05766605Written as Lobaplatin
- Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled TrialRecruitingPhase 3Zhujiang HospitalNCT05701436Written as Lobaplatin
- Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal ChemotherapyNot yet recruitingPhase 2Wuhan Union Hospital, ChinaNCT04845490Written as Lobaplatin
- Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal ChemotherapyRecruitingPhase 2Wuhan Union Hospital, ChinaNCT04808466Written as Lobaplatin
- Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast CancerStatus unknownPhase 2Chinese Academy of Medical SciencesNCT05546255Written as Lobaplatin
- Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal CarcinomaCompletedPhase 4Henan Cancer HospitalNCT03413436Written as Lobaplatin
- Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung CancerStatus unknownPhase 2Guizhou Medical UniversityNCT03613597Written as etoposide plus lobaplatin
- Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung CancerStatus unknownPhase 2ShengFa SuNCT03613753Written as irinotecan plus lobaplatin
- Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical TrialCompletedPhase 1Fifth Affiliated Hospital, Sun Yat-Sen UniversityNCT03188497Written as Lobaplatin
- A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.Status unknownPhase 2Sun Yat-sen UniversityNCT03210389Written as Lobaplatin
- Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHNStatus unknownPhase 2Guiyang Medical UniversityNCT03117257Written as Lobaplatin
- A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced OsteosarcomaStatus unknownPhase 2/3China Association of Osteosarcoma ChemotherapyNCT02099396Written as Docetaxel+lobaplatin
- Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast CancerStatus unknownPhase 2Harbin Medical UniversityNCT01483300Written as lobaplatin
- Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Esophageal CarcinomaStatus unknownPhase 3Taian Cancer HospitalNCT01034683Written as lobaplatin , 5-FU ,leucovorin
Given in every arm · 5 — lobaplatin is usual care beside what is tested
- Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of OsteosarcomaRecruitingPhase 2Peking University People's HospitalNCT06714383Written as Lobaplatin
- Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06170697Written as Lobaplatin
- A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPCNot yet recruitingPhase 3Sun Yat-sen UniversityNCT05780294Written as Lobaplatin
- A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLCStatus unknownPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT03700359Written as Lobaplatin
- Combine TACE and RFA Versus TACE Alone for HCC With PVTTStatus unknownPhase 3Ming ZhaoNCT02301091Written as pirarubicin,mitomycin and lobaplatin
Codes
What other systems call lobaplatin · ClinicalTrials.gg INT003538
- MeSH (NLM) C066228lobaplatinOne source NLM
- UNII (FDA) OX5XK1JD8CLOBAPLATINConfirmed FDA, NLM, Wikidata
- Wikidata Q72487668lobaplatinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1434LobaplatinOne source FDA
- DrugBank DB13049One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C066228 | lobaplatin | One source NLM |
| UNII (FDA) | OX5XK1JD8C | LOBAPLATIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q72487668 | lobaplatin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1434 | Lobaplatin | One source FDA |
| DrugBank | DB13049 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.